Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gastrointestinal 3Breast 2Thoracic 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1

Interventions

fludarabine phosphate 113Cyclophosphamide 97Whole-Body Irradiation 82Mycophenolic Acid 79fludarabine 74Tacrolimus 69Busulfan 68Azacitidine 62Peripheral Blood Stem Cell Transplantation 59Melphalan 48Cytarabine 48Antilymphocyte Serum 47Methotrexate 45Cyclosporine 45Filgrastim 39Imatinib Mesylate 37Granulocyte Colony-Stimulating Factor 37Decitabine 35nilotinib 34thymoglobulin 31ruxolitinib 29Thiotepa 27Stem Cell Transplantation 23Clofarabine 22Alemtuzumab 21Rituximab 19Dasatinib 19Cord Blood Stem Cell Transplantation 19sargramostim 17Sirolimus 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × CB-839 × Myeloid × Clear all
NCT03047993 2024-05-14

Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome

M.D. Anderson Cancer Center

Phase 1/2 Completed
28 enrolled 8 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡